Longevity & biohacking

Aging backwards: NewLimit raises $435m to rewrite longevity science — Photo by cottonbro studio on Pexels

longevity science is overhyped but this research really could change humanity

Longevity Science Overhyped? This Research Is Game‑Changing

In 2026, NewLimit secured $435 million to fast-track longevity drug trials. This infusion of capital is compressing development timelines and bringing age-targeted therapies closer to market. As investors rally behind the promise of longer, healthier lives, the field is shifting from buzzwords to tangible progress. Medical Disclaimer: This article is